ai3Bio
ai3Bio develops therapies designed to remove disease-causing Th17 immune cells, using antibody and lipid-nanoparticle platforms to address autoimmune disease.
$48MSeries A
ParticipantCI
Cockrell Interests
Activity from announced rounds
Activity in this selectionUnited States
Cockrell Interests is the investment entity named in financing coverage for Stellular Bio and ai3Bio.
Recorded funding activity
Stellular develops platelet-derived biologic therapies for ocular-surface diseases. ai3Bio develops antibody and lipid-nanoparticle approaches intended to remove disease-causing Th17 immune cells. The company records connect the same named investor to distinct therapeutic programs.
- Rounds participated in
- 2
- Confirmed lead rounds
- 0 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $48M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in this selectionStellular Bio
Develops platelet-derived regenerative biologic therapeutics for ocular surface diseases
UndisclosedSeries A
Role not disclosed